Early trial tests Immune-Boosting drugs with chemo for tough cancers
NCT ID NCT03245892
Summary
This small, early-stage study aimed to find out if it was safe to add one or two immunotherapy drugs (nivolumab and ipilimumab) to the standard chemotherapy used for advanced ovarian, fallopian tube, or primary peritoneal cancer. It involved 27 patients with advanced disease who were scheduled to receive chemotherapy before and after surgery. The main goal was to check for serious side effects to see if this combined approach could be studied further.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.